Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Lava Therapeutics (Netherlands) | Researchclopedia

Back to institutions

Lava Therapeutics (Netherlands)

Utrechtcompany

65

Works

3,818

Citations

31

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research Immune Cell Function and Interaction

Top Researchers

Paul W.H.I. Parren Leiden University Medical Center

472 works31,725 citationsh-index: 96

Recent Research

PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment

Lisa A. King,Myrthe Veth,et al.

20251 citations

T-cell and B-cell Immunology

Immunotherapy and Immune Responses

Cancer Immunotherapy and Biomarkers

Complement system in diseases

Colorectal Cancer Treatments and Studies

Hepatocellular Carcinoma Treatment and Prognosis

Lymphoma Diagnosis and Treatment

Glycosylation and Glycoproteins Research

HER2/EGFR in Cancer Research

Hans van Vliet Lava Therapeutics (Netherlands)

509 works15,859 citationsh-index: 64

Rob C. Roovers Utrecht University

93 works5,448 citationsh-index: 35

Sigrid R. Ruuls Utrecht University

36 works3,090 citationsh-index: 21

Benjamin Winograd Lava Therapeutics (Netherlands)

67 works2,927 citationsh-index: 23

Teeru Bihani Lava Therapeutics (Netherlands)

73 works1,490 citationsh-index: 15

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager

Lisa A. King,Myrthe Veth,et al.

20243 citations

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion

Lisa A. King,Milon de Jong,et al.

20242 citations

Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).

Niven Mehra,Jens Voortman,et al.

20247 citations

Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells

Aram de Haas,Dorian A. Stolk,et al.

20243 citations

Integrative Kinase Activity Profiling and Phosphoproteomics of rd10 Mouse Retina during cGMP-Dependent Retinal Degeneration

Akanksha Roy,Jiaming Zhou,et al.

20245 citations